Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary New recruit expands senior team capabilities as the business progresses ...

New recruit expands senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the treatment of Charcot-Marie-Tooth Disease and continues ...

Tumor immunotherapy has become a standard of care for treating various cancers, with immune checkpoint inhibitors targeting the PD-L1/PD-1 axis proving particularly effective. While PD-L1 expression ...

An experimental new treatment is showing early promise in the fight against liver fibrosis—a serious and often silent ...

The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements and were granted as an inducement ...

Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...